Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Hormone-refractory Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: eribulin mesylate

Registration Number: NCT00337077

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog) works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Detailed Description: PRIMARY OBJECTIVES:

I. Determine the number of patients with a \> 50% decrease in prostate-specific antigen (PSA) of at least 4 weeks duration in patients with hormone-refractory metastatic prostate cancer treated with E7389 (eribulin mesylate).

SECONDARY OBJECTIVES:

I. Estimate the measurable disease response in patients with measurable disease.

II. Determine the duration of PSA and measurable disease response.

III. Characterize the safety and tolerability of E7389 in these patients.

OUTLINE:

This study enrolled 3 cohorts of patients based on the number of prior chemotherapy regimens received. The 3 cohorts are chemonaive stratum, prior-taxane stratum, and two-prior-chemotherapy stratum. Patients receive eribulin mesylate intravenously (IV) over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 121

Inclusion Criteria

Histologically confirmed adenocarcinoma of the prostate
Progressive metastatic disease or stable metastatic disease with rising PSA
Previously treated with bilateral orchiectomy or other primary hormonal therapy with evidence of treatment failure
Patients who have not undergone bilateral orchiectomy must continue luteinizing hormone-releasing hormone (LHRH)-agonist therapy (e.g., leuprolide or goserelin) or LHRH antagonist therapy (e.g. abarelix) while receiving study treatment
Patients who did not have an orchiectomy must have a testosterone level < 50 ng/dL to confirm androgen suppression within the past 4 weeks
ECOG performance status 0-2
Adequate bone marrow function
Bilirubin =< 1.5 mg/dL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times upper limit of normal
Creatinine =< 2.0 mg/dL OR creatinine clearance >= 40 mL/min
Fertile patients must use effective contraception
A taxane-based regimen, mitoxantrone, or other cytotoxic chemotherapy regimen allowed provided there is evidence of disease progression
At least 4 weeks since prior chemotherapy or radiotherapy
At least 4 weeks since prior flutamide (6 weeks for bicalutamide or nilutamide) and there is continued evidence of disease progression
Disease progression after antiandrogen withdrawal must be confirmed by rising PSA after the required 4-6 week washout period (e.g., PSA level higher than the last PSA obtained while on antiandrogen therapy)
More than 4 weeks since prior estrogen, estrogen-like agents (e.g., PC-SPES, saw palmetto, or other herbal products that may contain phytoestrogens), or any other hormonal therapy (including megestrol, finasteride, ketoconazole, or systemic corticosteroids)
Concurrent bisphosphonates (e.g., pamidronate sodium or zoledronate) allowed provided the patient has been receiving the bisphosphonate for >= 4 weeks and there is evidence of disease progression

Exclusion Criteria

Active angina pectoris
Known New York Heart Association class III-IV heart disease
Myocardial infarction within the past 6 months
Evidence of ventricular dysrhythmias or other unstable arrhythmia (rate-controlled atrial fibrillation is allowed if the patient is asymptomatic from a cardiac standpoint)
Peripheral neuropathy > grade 2
Other prior malignancy (excluding nonmelanomatous skin cancer treated with curative intent) unless the malignancy was treated with curative intent and the patient has been disease free for >= 5 years
Serious concurrent medical illness or active infection that would preclude study treatment - No concurrent strong inhibitors or inducers of CYP3A4
More than 2 prior chemotherapy regimens for hormone-refractory disease - Other concurrent investigational agents
Other concurrent anticancer therapy, including chemotherapy, gene therapy, biologic therapy, or immunotherapy
Concurrent palliative radiotherapy
Concurrent estrogen, estrogen-like agents, or any other hormonal therapy
Carcinomatous meningitis or brain metastases
Prior strontium chloride Sr 89, samarium 153 lexidronam pentasodium, or other radioisotopes
Concurrent therapeutic anticoagulation with warfarin (Unfractionated heparin [standard, low-dose, or adjusted dose] or low molecular weight heparin allowed

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Eribulin mesylate	eribulin mesylate	Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures

Name	Time	Method
Proportion of Patients With PSA Response	Assessed every 3 weeks during treatment; after off-treatment, every 3 months if patient is <2 years from study entry and every 6 months if patient is 2-5 years	PSA response is defined as a PSA decline from baseline value by \>=50%, or normalization of PSA (\<0.2 ng/ml) confirmed by a second measurement greater than or equal to 4 weeks later.

Secondary Outcome Measures

Name	Time	Method
Proportion of Patients With Measurable Disease Response	Assessed every 9 weeks during treatment; after off-treatment, every 3 months if patient is <2 years from study entry and every 6 months if patient is 2-5 years from study entry	Measurable disease response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) 1.0 criteria. Per RECIST criteria, complete response (CR) = disappearance of all target and non-target lesions. Partial response (PR)= \>=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits. Measurable disease response = CR + PR. Only patients with measurable disease at baseline are included in this analysis.

Trial Locations

Locations (146): Mayo Clinic in Arizona
🇺🇸
Scottsdale, Arizona, United States
Community Hospital of Monterey Peninsula
🇺🇸
Monterey, California, United States
Manchester Memorial Hospital
🇺🇸
Manchester, Connecticut, United States
Boca Raton Regional Hospital
🇺🇸
Boca Raton, Florida, United States
Mayo Clinic in Florida
🇺🇸
Jacksonville, Florida, United States
Rush - Copley Medical Center
🇺🇸
Aurora, Illinois, United States
Saint Joseph Medical Center
🇺🇸
Bloomington, Illinois, United States
Graham Hospital Association
🇺🇸
Canton, Illinois, United States
Memorial Hospital
🇺🇸
Carthage, Illinois, United States
Mercy Hospital and Medical Center
🇺🇸
Chicago, Illinois, United States
Scroll for more (136 remaining)
Mayo Clinic in Arizona
🇺🇸Scottsdale, Arizona, United States